PALISADE BIO, INC. (PALI) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -35.35M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | (m) | Research and Development Expense |
| Selling, general and administration | (m) | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-35.35M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $-26.49M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $-18.06M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $-11.46M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $-12.13M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $-13.50M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $-14.86M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-09-30 | $-14.63M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-06-30 | $-14.82M | $0.00 | (m) | (m) | (m) | (m) |
| 2024-03-31 | $-14.21M | $0.00 | (m) | (m) | (m) | (m) |
| 2023-12-31 | $-13.07M | $250.00K | (m) | (m) | (m) | -5228.00% |
| 2023-09-30 | $-13.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $-14.40M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $-14.36M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-15.72M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $-15.90M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $-14.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $-43.79M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $-41.85M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $-42.45M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $-41.25M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-10.88M | (m) | (m) | $1.79M | (m) | (m) |
| 2020-12-31 | $-10.68M | (m) | (m) | $2.02M | (m) | (m) |
| 2020-09-30 | $-8.41M | (m) | (m) | $2.38M | (m) | (m) |
| 2020-06-30 | $-8.19M | (m) | (m) | $2.74M | (m) | (m) |
| 2020-03-31 | $-8.17M | (m) | (m) | $3.24M | (m) | (m) |
| 2019-12-31 | $-8.63M | (m) | (m) | $4.06M | (m) | (m) |
| 2019-09-30 | $-8.30M | (m) | (m) | $4.17M | (m) | (m) |
| 2019-06-30 | $-8.26M | (m) | (m) | $4.24M | (m) | (m) |
| 2019-03-31 | $-8.37M | (m) | (m) | $4.31M | (m) | (m) |
| 2018-12-31 | $-8.26M | (m) | (m) | $3.96M | (m) | (m) |
| 2018-09-30 | $-8.72M | (m) | (m) | $4.31M | (m) | (m) |
| 2018-06-30 | $-9.23M | (m) | (m) | $4.79M | (m) | (m) |
| 2018-03-31 | $-11.42M | (m) | (m) | $6.36M | (m) | (m) |
| 2017-12-31 | $-13.31M | $260.00K | (m) | $8.10M | (m) | -5118.12% |
| 2017-09-30 | $-16.69M | $16.25K | (m) | $10.90M | (m) | -102733.40% |
| 2017-06-30 | $-19.02M | $16.25K | (m) | $13.10M | (m) | -117070.05% |
| 2017-03-31 | $-18.64M | $16.25K | (m) | $12.99M | (m) | -114706.62% |
| 2016-12-31 | $-20.64M | $16.25K | (m) | $13.16M | (m) | -127027.23% |
| 2016-09-30 | $-19.34M | $10.00K | (m) | $11.88M | (m) | -193361.92% |
| 2016-06-30 | $-19.62M | $10.00K | (m) | $11.68M | (m) | -196167.07% |
| 2016-03-31 | $-20.78M | $10.00K | (m) | $12.52M | (m) | -207771.60% |
| 2015-12-31 | $-19.16M | $10.42K | (m) | $12.64M | (m) | -183896.78% |
| 2015-09-30 | $-19.45M | $12.58K | (m) | $12.27M | (m) | -154543.33% |
| 2015-06-30 | $-18.36M | $15.08K | (m) | $11.00M | (m) | -121696.03% |
| 2015-03-31 | $-16.87M | $17.58K | (m) | $9.69M | (m) | -95955.91% |
| 2014-12-31 | $-17.44M | $18.83K | (m) | $8.13M | (m) | -92581.37% |
| 2014-09-30 | $-15.56M | $16.67K | (m) | $7.21M | (m) | -93342.88% |
| 2014-06-30 | $-15.08M | $14.17K | (m) | $7.00M | (m) | -106477.72% |
| 2014-03-31 | $-14.81M | $11.67K | (m) | $6.96M | (m) | -126931.19% |
| 2013-12-31 | $-12.52M | $110.00K | (m) | $7.13M | (m) | -11385.40% |
| 2013-09-30 | $-12.49M | $110.00K | (m) | $7.20M | (m) | -11352.90% |
| 2013-06-30 | $-11.44M | $278.33K | (m) | $6.74M | (m) | -4109.24% |
| 2013-03-31 | $-10.59M | $353.96K | (m) | $6.43M | (m) | -2990.47% |
| 2012-12-31 | $-10.16M | $407.71K | (m) | $6.11M | $256.00K | -2491.11% |
| 2012-09-30 | $-9.99M | $692.42K | (m) | $5.81M | (m) | -1443.01% |
| 2012-06-30 | $-10.63M | $625.00K | (m) | $6.55M | (m) | -1701.05% |
| 2012-03-31 | $-11.92M | (m) | (m) | $7.04M | (m) | (m) |
| 2011-12-31 | $-12.99M | $390.63K | (m) | $7.35M | (m) | -3325.56% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-15.18M | $733.44K | (m) | $9.16M | (m) | -2070.37% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-10.47M | (m) | (m) | $5.35M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |